2015;238:329 35. S5-21. Banach M, Serban C, Sahebkar A, et al. Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. Mayo Clin Proc. 2015;90:24 34. S5-22. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170000 participants in 26 randomised trials. Lancet. 2010;376:1670 81. S5-23. Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388: 2532 61. S5-24. Yusuf S, Bosch J, Dagenais G, et al. Cholesterol lowering in inter- mediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374:2021 31. S5-25. Bruckert E, Hayem G, Dejager S, et al. Mild to moderate mus- cular symptoms with high-dosage statin therapy in hyper- lipidemic patients the PRIMO study. Cardiovasc Drugs Ther. 2005;19:403 14. S5-26. Cohen JD, Brinton EA, Ito MK, et al. Understanding statin Use in America and Gaps in Patient Education (USAGE): an Internet-based survey of 10138 current and former statin users. J Clin Lipidol. 2012;6:208 15. S5-27. Serban MC, Colantonio LD, Manthripragada AD, et al. Statin Intolerance and Risk of Coronary Heart Events and All-cause mortality following myocardial infarction. J Am Coll Cardiol. 2017;69:1386 95. S5-28. Zhang H, Plutzky J, Shubina M, et al. Continued statin prescriptions after adverse reactions and patient outcomes: a cohort study. Ann Intern Med. 2017;167:221 7. S5-29. Zhang H, Plutzky J, Skentzos S, et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med. 2013;158:526 34. S5-30. Ganga HV, Slim HB, Thompson PD. A systematic review of statin-induced muscle problems in clinical trials. Am Heart J. 2014;168:6 15. S5-31. Mampuya WM, Frid D, Rocco M, et al. Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience. 